Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of DS-1055a in relapsed or refractory advanced solid tumors
jRCT2080225196Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of DS-1055a in Nonhematologic neoplasms, head and neck cancer (HNC), gastric cancer (GC) and 3 more, sponsored by Daiichi Sankyo Co., Ltd. Started May 2020; status: completed.
02
Drugs
DS-1055a
03
Conditions
Nonhematologic neoplasmshead and neck cancer (HNC)gastric cancer (GC)esophageal cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080225196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225196.